Thrombus formation after catheter closure of intra-atrial shunts occurred in 20 of 1000 patients, with the Amplatzer device showing a significantly lower incidence (0%) than other devices (p<0.05).
Observational (n=1,000)
Does the type of closure device affect the incidence of thrombus formation in patients undergoing transcatheter closure of intra-atrial shunts?
Thrombus formation on intra-atrial shunt closure devices is generally low (2.0%) and usually resolves with anticoagulation, but the incidence varies significantly depending on the specific device used.
OBJECTIVES: The purpose of this study was to investigate the incidence, morphology, and clinical course of thrombus formation after catheter closure of intra-atrial shunts. BACKGROUND: Post-procedure detailed information about thrombotic material on different devices for transcatheter closure is missing. METHOD: A total of 1,000 consecutive patients were investigated after patent foramen ovale (PFO) (n = 593) or atrial septal defect (ASD) (n = 407) closure. Transesophageal echocardiography (TEE) was scheduled after four weeks and six months. Additional TEEs were performed as clinically indicated. RESULTS: Thrombus formation in the left atrium (n = 11), right atrium (n = 6), or both (n = 3) was found in 5 of the 407 (1.2%) ASD patients and in 15 of the 593 (2.5%) PFO patients (p = NS). The thrombus was diagnosed in 14 of 20 patients after four weeks and in 6 of 20 patients later on. The incidence was: 7.1% in the CardioSEAL device (NMT Medical, Boston, Massachusetts); 5.7% in the StarFLEX device (NMT Medical); 6.6% in the PFO-Star device (Applied Biometrics Inc., Burnsville, Minnesota); 3.6% in the ASDOS device (Dr. Ing, Osypka Corp., Grenzach-Wyhlen, Germany); 0.8% in the Helex device (W.L. Gore and Associates, Flagstaff, Arizona); and 0% in the Amplatzer device (AGA Medical Corp., Golden Valley, Minnesota). The difference between the Amplatzer device on one hand and the CardioSEAL device, the StarFLEX device, and the PFO-Star device on the other hand was significant (p < 0.05). A pre-thrombotic disorder as a possible cause of the thrombus was found in two PFO patients. Post-procedure atrial fibrillation (n = 4) and persistent atrial septal aneurysm (n = 4) had been found as significant predictors for thrombus formation (p < 0.05). In 17 of the 20 patients, the thrombus resolved under anticoagulation therapy with heparin or warfarin. In three patients, the thrombus was removed surgically. CONCLUSIONS: The incidence of thrombus formation on closure devices is low. The thrombus usually resolves under anticoagulation therapy.
Krumsdorf et al. (Thu,) conducted a observational in Patent foramen ovale (PFO) or atrial septal defect (ASD) (n=1,000). Catheter closure devices was evaluated on Thrombus formation. Thrombus formation after catheter closure of intra-atrial shunts occurred in 20 of 1000 patients, with the Amplatzer device showing a significantly lower incidence (0%) than other devices (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: